featured
Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial
JAMA Oncol 2021 Sep 16;[EPub Ahead of Print], WF Symmans, C Yau, YY Chen, R Balassanian, ME Klein, L Pusztai, R Nanda, BA Parker, B Datnow, G Krings, S Wei, MD Feldman, X Duan, B Chen, H Sattar, L Khazai, JC Zeck, S Sams, P Mhawech-Fauceglia, M Rendi, S Sahoo, IT Ocal, F Fan, LG LeBeau, T Vinh, ML Troxell, AJ Chien, AM Wallace, A Forero-Torres, E Ellis, KS Albain, RK Murthy, JC Boughey, MC Liu, BB Haley, AD Elias, AS Clark, K Kemmer, C Isaacs, JE Lang, HS Han, K Edmiston, RK Viscusi, DW Northfelt, QJ Khan, B Leyland-Jones, SJ Venters, S Shad, JB Matthews, SM Asare, M Buxton, AL Asare, HS Rugo, RB Schwab, T Helsten, NM Hylton, L van 't Veer, J Perlmutter, AM DeMichele, D Yee, DA Berry, LJ EssermanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.